Stock listing
A1W7D4 Stock Price, News, Filings & Events — Aurinia Pharmaceuticals Inc
Selected listing: A1W7D4 · LS · EUR · DE
This page tracks Aurinia Pharmaceuticals Inc's A1W7D4:LS listing on LS in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following A1W7D4:LS. A1W7D4:LS is the stock-level entry point for investors researching Aurinia Pharmaceuticals Inc, while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Aurinia Pharmaceuticals Inc (Ticker: AUPH) is a public company based in the United States, focused on developing innovative therapies for kidney diseases. With a market capitalization of approximately $1.97 billion, Aurinia is dedicated to advancing its pipeline of treatments to improve patient outcomes. The company is committed to addressing unmet medical needs in the healthcare sector.
- Ticker
- A1W7D4:LS
- Asset type
- Stock
- Market cap
- $2.14B
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- LS
- Currency
- EUR
Aurinia Pharmaceuticals Inc A1W7D4:LS stock context
This page tracks Aurinia Pharmaceuticals Inc's A1W7D4:LS listing on LS in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following A1W7D4:LS. A1W7D4:LS is the stock-level entry point for investors researching Aurinia Pharmaceuticals Inc, while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Aurinia Pharmaceuticals Inc (Ticker: AUPH) is a public company based in the United States, focused on developing innovative therapies for kidney diseases. With a market capitalization of approximately $1.97 billion, Aurinia is dedicated to advancing its pipeline of treatments to improve patient outcomes. The company is committed to addressing unmet medical needs in the healthcare sector.
Latest news from Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business...
August 6, 2026
Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in...
July 6, 2026
LUPKYNIS Associated with a Statistically Significant 53% Reduction in Risk of Renal-Related Event or Death
June 4, 2026
TANG CAPITAL MANAGEMENT, LLC FILES EARLY WARNING REPORT RESPECTING AURINIA PHARMACEUTICALS INC.
June 3, 2026
Aurinia Pharmaceuticals Completes Successful Tender Offer for Kezar Life Sciences
May 19, 2026
Aurinia Pharmaceuticals Inc earnings calls
Aurinia Pharmaceuticals Inc (AUPH) Q4 2025 Earnings Call
February 26, 2026 · Replay with transcript and chapters
Aurinia Pharmaceuticals Inc (AUPH) Q3 2025 Earnings Call
November 4, 2025 · Replay with transcript and chapters
Aurinia Pharmaceuticals Inc (AUPH) Q2 2025 Earnings Call
July 31, 2025 · Replay with transcript and chapters
Aurinia Pharmaceuticals Inc (AUPH) Q1 2025 Earnings Call
May 12, 2025 · Replay with transcript and chapters
Aurinia Pharmaceuticals Inc (AUPH) Q4 2024 Earnings Call
February 27, 2025 · Replay with transcript and chapters
Aurinia Pharmaceuticals Inc (AUPH) Q3 2024 Earnings Call
November 7, 2024 · Replay with transcript and chapters
Research Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc investor report
Review AI stock analysis and investor report context for A1W7D4:LS.
Aurinia Pharmaceuticals Inc company profile
View the public company page for Aurinia Pharmaceuticals Inc on 6ix.
Aurinia Pharmaceuticals Inc news
Read company news and market updates connected to Aurinia Pharmaceuticals Inc.
Aurinia Pharmaceuticals Inc investor events
Find investor webinars, events, and replay context for Aurinia Pharmaceuticals Inc.
Alternate listings
AUPH:NASDAQ
US · USD
Alternate listing for Aurinia Pharmaceuticals Inc; the primary context on this page is A1W7D4:LS.
IKAP:GETTEX
DE · EUR
Alternate listing for Aurinia Pharmaceuticals Inc; the primary context on this page is A1W7D4:LS.
A1W7D4:LSX
DE · EUR
Alternate listing for Aurinia Pharmaceuticals Inc; the primary context on this page is A1W7D4:LS.
AUPH:BOATS
US · USD
Alternate listing for Aurinia Pharmaceuticals Inc; the primary context on this page is A1W7D4:LS.
IKAP:FWB
DE · EUR
Alternate listing for Aurinia Pharmaceuticals Inc; the primary context on this page is A1W7D4:LS.
0UJF:LSE
GB · CAD
Alternate listing for Aurinia Pharmaceuticals Inc; the primary context on this page is A1W7D4:LS.
IKAP:SWB
DE · EUR
Alternate listing for Aurinia Pharmaceuticals Inc; the primary context on this page is A1W7D4:LS.
IKAP:TRADEGATE
DE · EUR
Alternate listing for Aurinia Pharmaceuticals Inc; the primary context on this page is A1W7D4:LS.
IKAP:DUS
DE · EUR
Alternate listing for Aurinia Pharmaceuticals Inc; the primary context on this page is A1W7D4:LS.
IKAP:MUN
DE · EUR
Alternate listing for Aurinia Pharmaceuticals Inc; the primary context on this page is A1W7D4:LS.